Após nove meses de investigação, a Agência Europeia de Medicamentos concluiu que a semaglutida — princípio ativo do Ozempic e do Wegovy — não apresenta evidências de associação com pensamentos suicidas. A conclusão, alinhada à dos reguladores americanos, encerra uma fase de incerteza iniciada quando a Islândia sinalizou três casos suspeitos. O episódio lembra que, à medida que milhões adotam novas terapias, a vigilância regulatória não é burocracia, mas uma forma de cuidado coletivo — especialmente quando a história já registrou retiradas dolorosas, como a do Acomplia em 2008.
Folha de S.Paulo
· Apr 12, 2024
· health
· 3 min read
High
Sourcing: Verified
EU regulator finds no link between Ozempic and suicidal thoughts after 9-month review
◉
Health & Medicine
2821 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Related Coverage
REDE BRASIL DE TELEVISÃO · Aug 25
Endocrinologista explica por que emagrecer após os 40 exige abordagem integral
Endocrinologista explica que perda de peso após os 40 anos exige análise integrada de hormônios, sono e composição corpo…
Folha de S.Paulo · Aug 25 Zema critica vacinação obrigatória e nega golpe em entrevista ao Jornal NacionalCandidato presidencial Romeu Zema declarou-se contrário à vacinação obrigatória e prometeu anistia aos condenados pelos …
Super Rádio Tupi · Aug 25 Nova espécie de cão-urso do Mioceno revela predador pré-histórico desconhecidoPesquisadores identificaram uma nova espécie de cão-urso (anficionídeo) em fósseis de 16 milhões de anos, ampliando o co…
REDE BRASIL DE TELEVISÃO · Aug 25 Diagnóstico precoce de Alzheimer amplia possibilidades de tratamento, alerta FebrazCampanha Setembro Lilás 2026 alerta sobre importância do diagnóstico inicial de Alzheimer, com 84,3% de subdiagnóstico n…
Bias & Framing
⚖
Article presents EU regulator's reassuring conclusion on Ozempic safety with minimal critical context, favoring pharmaceutical industry narrative.
Bias Direction
center-right
Confidence
MED
Reassurance framing emphasizing regulatory clearance and stock market gains, with limited exploration of initial safety concerns or ongoing monitoring limitations.
descartada (dismissed/ruled out) - suggests concerns were unfounded rather than investigated
não encontrou evidências (found no evidence) - definitive language despite ongoing monitoring
as ações da Novo Nordisk aumentaram quase 2% (stock increased) - implies market validation of safety
Patient testimonies or advocacy groups who reported adverse effects
Independent medical researchers or skeptical experts questioning the review methodology
Details on the three Icelandic cases that triggered the investigation
Limitations of the 9-month review period or data gaps acknowledged by regulators
Comparative analysis with other GLP-1 drugs and their safety profiles
Long-term monitoring plans or post-market surveillance details
Geopolitical Impact
🌎
EU regulator clears semaglutida (Ozempic/Wegovy) of suicide risk after 9-month review, aligning with US findings and boosting Novo Nordisk's market position across transatlantic markets.
Escalation Risk
low
Confidence
HIGH
European Union
United States
Iceland
Denmark
Novo Nordisk strengthens its regulatory standing and market dominance in the lucrative GLP-1 agonist sector across EU and US markets. EU-US regulatory alignment enhances pharmaceutical industry confidence and reduces fragmentation risks. Iceland's initial safety concerns were overridden by larger regulatory bodies, reflecting power concentration in major regulatory agencies.
Similar to the 2010s statin controversy where initial safety concerns were systematically investigated and largely dismissed by major regulators, reinforcing trust in pharmaceutical oversight mechanisms while occasionally frustrating patient advocacy groups.
Economic Lens
📈
EU regulator clears semaglutida (Ozempic/Wegovy) of suicide risk after 9-month review, boosting Novo Nordisk stock ~2% and reducing regulatory uncertainty for GLP-1 drug class.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Medical Devices
Insurance (Health)
Wellness & Weight Management
Consumers gain confidence in GLP-1 medications for diabetes and weight loss without psychiatric safety concerns. Reduced hesitation for prescription adoption and continued off-label use. Lower insurance claim denials related to psychiatric adverse events.
Regulatory clearance reduces likelihood of label warnings or market restrictions in EU. May accelerate approval timelines for competing GLP-1 drugs. Establishes precedent for pharmacovigilance standards on psychiatric safety in metabolic drugs. Potential for harmonized international safety guidance.